title: [Renal cysts - A novel complication of crizotinib treatment for lung cancer].
abstract: We report the case of a woman with an ALK positive lung adenocarcinoma, who developed bilateral complex renal cysts 17 months after the introduction of treatment with crizotinib. Clinical investigation led to the conclusion that the cysts were due to anticancer drug. Regression of the renal cysts was observed one month after cessation of the crizotinib. This case illustrates that specific and little known toxicities can occur with these novel molecules which have entered use for the management of lung cancer.
authors.affiliation: Service des soins intensifs et urgences oncologiques, clinique d'oncologie thoracique, institut Jules-Bordet, centre des tumeurs de l'Université Libre de Bruxelles, rue, Héger-Bordet, 1, 1000 Bruxelles, Belgique.
authors.forename: I
authors.initials: I
authors.lastname: CsToth
authors.affiliation: Service des soins intensifs et urgences oncologiques, clinique d'oncologie thoracique, institut Jules-Bordet, centre des tumeurs de l'Université Libre de Bruxelles, rue, Héger-Bordet, 1, 1000 Bruxelles, Belgique.
authors.forename: A-P
authors.initials: AP
authors.lastname: Meert
authors.affiliation: Service des soins intensifs et urgences oncologiques, clinique d'oncologie thoracique, institut Jules-Bordet, centre des tumeurs de l'Université Libre de Bruxelles, rue, Héger-Bordet, 1, 1000 Bruxelles, Belgique.
authors.forename: J-P
authors.initials: JP
authors.lastname: Sculier
authors.affiliation: Service des soins intensifs et urgences oncologiques, clinique d'oncologie thoracique, institut Jules-Bordet, centre des tumeurs de l'Université Libre de Bruxelles, rue, Héger-Bordet, 1, 1000 Bruxelles, Belgique. Electronic address: thierry.berghmans@bordet.be.
authors.forename: T
authors.initials: T
authors.lastname: Berghmans
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D000077547:Crizotinib; D005260:Female; D006801:Humans; D052177:Kidney Diseases, Cystic / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib
keywords: Cancer bronchique; Crizotinib; Kyste rénal; Lung cancer; Renal cysts